US FDA Finds Negligible Cancer Risks In Metformin Products
Executive Summary
The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.
You may also be interested in...
Metformin Testing Prompts New Finding Of NDMA And Cancer Risk
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
New Testing Prompts New Finding Of NDMA, Cancer Risk In Metformin Products
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
EMA Provides Update On Metformin Impurity Concerns
The European Medicines Agency has provided an update on the presence of potentially carcinogenic nitrosamines in certain medicines, including metformin, underlining that work is continuing to prevent and manage impurities.